News

Over a career spanning more than 25 years, Dr. Tomoko Takano has won the respect and gratitude of her peers and patients for her steadfast commitment to advancing understanding and treatment of kidney disease.

A new analysis from the Global Burden of Disease Study published in The Lancet in November 20251, shows that the impact of chronic kidney disease (CKD) has substantially increased over the past three decades.

Protecting the long-term health of their heart and kidneys is a major challenge for people with type 1 diabetes (T1D). Luckily, findings from the SUGARNSALT project demonstrate medications that can help with this.

This year (2025) marks a huge milestone for the Canadian Institutes of Health Research (CIHR) as it celebrates its 25th anniversary.

Shining a spotlight on the extraordinary volunteers who fuel its mission, The Kidney Foundation of Canada recently took the opportunity to laud these effects during its Annual Virtual Recognition Awards.

KRESCENT is Canada’s elite kidney health research training program – supporting the next generation of kidney health researchers for the past 20 years.

You are passionate about people, you are looking for a way to help, this one is for you!

Health Canada has approved Ozempic (semaglutide) for people living with type 2 diabetes and chronic kidney disease.

The Kidney Foundation of Canada stands firm for every Canadian living with or at risk of kidney disease – no matter who they are, where they live, or where they are on their kidney journey.

In a landmark moment for global health, the World Health Assembly (WHA78) has adopted its first ever resolution focused exclusively on kidney health.

A patient’s journey on dialysis can be difficult not just physically but mentally and emotionally as well.

For over 25 years, Dr. Tomoko Takano has been a leader in the Canadian nephrology research community.